Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J. du Bois A, et al. Among authors: burges a. J Clin Oncol. 2010 Sep 20;28(27):4162-9. doi: 10.1200/JCO.2009.27.4696. Epub 2010 Aug 23. J Clin Oncol. 2010. PMID: 20733132 Clinical Trial.
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
du Bois A, Belau A, Wagner U, Pfisterer J, Schmalfeldt B, Richter B, Staehle A, Jackisch C, Lueck HJ, Schroeder W, Burges A, Olbricht S, Elser G; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). du Bois A, et al. Among authors: burges a. Gynecol Oncol. 2005 Feb;96(2):444-51. doi: 10.1016/j.ygyno.2004.10.020. Gynecol Oncol. 2005. PMID: 15661234 Clinical Trial.
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group.
Hilpert F, Stähle A, Tomé O, Burges A, Rossner D, Späthe K, Heilmann V, Richter B, du Bois A; Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Hilpert F, et al. Among authors: burges a. Support Care Cancer. 2005 Oct;13(10):797-805. doi: 10.1007/s00520-005-0782-y. Epub 2005 Jul 16. Support Care Cancer. 2005. PMID: 16025262 Clinical Trial.
Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Hoppenau B, du Bois A; AGO-OVAR. Wimberger P, et al. Among authors: burges a. Gynecol Oncol. 2006 Feb;100(2):300-7. doi: 10.1016/j.ygyno.2005.08.029. Epub 2005 Sep 29. Gynecol Oncol. 2006. PMID: 16199079 Clinical Trial.
Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).
du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B, Jackisch C, Staehle A, Kimmig R, Elser G; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom. du Bois A, et al. Among authors: burges a. Ann Oncol. 2006 Jan;17(1):93-6. doi: 10.1093/annonc/mdj032. Epub 2005 Nov 9. Ann Oncol. 2006. PMID: 16282248 Free article. Clinical Trial.
The role of surgery in recurrent ovarian cancer.
Pfisterer J, Harter P, Canzler U, Richter B, Jackisch C, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Bois A; AGO Ovarian Committee; AGO Ovarian Cancer Study Group (AGO-OVAR). Pfisterer J, et al. Among authors: burges a. Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:195-8. doi: 10.1111/j.1525-1438.2005.00430.x. Int J Gynecol Cancer. 2005. PMID: 16343230 Free article.
[Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO].
Schmalfeldt B, du Bois A, Burges A, Emons G, Fink D, Gropp M, Hasenburg A, Jäger W, Kimmig R, Kiechle M, Kommoss F, Kreienberg R, Kuhn W, Lück HJ, Meier W, Münstedt K, Ortmann O, Pfisterer J, Richter B, Runnebaum I, Schröder W, Sehouli J, Tanner B, Wagner U, Weis J. Schmalfeldt B, et al. Among authors: burges a. Zentralbl Gynakol. 2006 Feb;128(1):11-7. doi: 10.1055/s-2006-921345. Zentralbl Gynakol. 2006. PMID: 16450281 German.
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schröder W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Tanner B, Sehouli J; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee; AGO Ovarian Cancer Study Group. Harter P, et al. Among authors: burges a. Ann Surg Oncol. 2006 Dec;13(12):1702-10. doi: 10.1245/s10434-006-9058-0. Ann Surg Oncol. 2006. PMID: 17009163 Clinical Trial.
179 results